embryonic stem cell news from FierceBiotech
News
FDA's delay of Geron ESC trial raises concerns
Getting an embryonic stem cell therapy through clinical trials in the U.S. is looking like an increasingly tough challenge after Geron announced that the FDA is delaying a study of its experimental Read more...
Stem cell developers shift focus to FDA hearings
Everyone involved in embryonic stem cell programs will be paying close attention to hearings the FDA is holding on how they plan to regulate the field. Developers want a much clearer idea of the Read more...
Stem cell outfits a winner in upcoming election
The nation's top biotech analysts have looked over the field of presidential candidates and announced a big winner: Stem cell companies. Read more...
The 2008 Election: What does it mean for drugmakers?
The winner of the 2008 election will be faced with making key decisions on a number of issues important to drug developers. Questions as to whether there will be more federal funding for stem cell Read more...
In research, stem cells make another breakthrough
Long before the most successful biotech companies advance a new therapy into the clinic, there was a scientist at work doing some painstaking research in the lab. To get a good look at Read more...
ALSO NOTED: Genitope's MyVax misses Phase III endpoint; Report: Pfizer looks at Danish biotechs; and much more...
> Genitope's MyVax, a treatment for follicular B-cell non-Hodgkin's lymphoma, has flunked a Phase III trial. There was no difference in progression-free survival between patients taking the drug Read more...
NJ stem cell initiative shot down at the polls
By all accounts, New Jersey's referendum to back embryonic stem cell research with $450 million in borrowed funds--working much like Read more...
Roche, GSK, AZ team up on stem cells
Three of Europe's biggest drugmakers have teamed up with the British government to launch Stem Cells for Safer Medicines (SC4SM), a non-profit that will develop stem cells for safety testing of new Read more...
Texas'$3B cancer program draws controversy
Texas voters will have the final say on a proposed $3 billion effort to support cancer research over 10 years inside the Lone Star state. This is the brainchild of the governor, who's clearly Read more...
SPOTLIGHT: Calif. stem cell agency struggles to keep talent
Assembling and keeping talent at California's stem cell agency continues to be a sore point. Interim scientific director Arlene Chiu has announced her resignation. The group is now the single Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends